When a drug benefit administered by CVS Caremark will not pay for Wegovy, four routes stay open: the manufacturer’s direct self-pay channel, a switch to an agent the plan already covers, a formal exception request, or a cash telehealth practice supplying compounded semaglutide, which is not an FDA-approved product. Price and clinical oversight differ sharply across the four.
“Not covered” describes two very different situations
CVS Caremark is a pharmacy benefit manager. It builds formularies, runs the claims adjudication system, and applies utilization rules, but it does all of that on behalf of a plan sponsor, which is normally an employer, a union fund, or a health plan. The sponsor decides whether drugs for chronic weight management belong in the benefit at all. The benefit manager then administers whatever the sponsor purchased.
That split explains why two people holding the same pharmacy card get opposite answers. One works for an employer that bought the weight-management category and needs an authorization on file. The other works for an employer that carved the category out, in which case there is no criterion to satisfy and no reviewer to persuade. Formulary documents are templates, revised at least annually and customized per client, so a PDF found through a search engine may not be the one governing a particular card.
The first task is not shopping. It is working out which of the two situations applies, by reading the plan’s own summary of benefits or asking the benefits administrator directly whether anti-obesity medication is a covered category this plan year.
Route one: the manufacturer’s self-pay channel
Novo Nordisk operates a direct channel priced for people paying without insurance, and separate savings arrangements exist for members whose commercial plan does cover the product and leaves a cost share. Those are two different offers with different terms, and both get revised. The figure worth writing down is the one quoted for the exact dose and pack size on the prescription, since some programs price starting doses differently from maintenance doses.
This route keeps the patient on the approved product whose prescribing information sits on DailyMed, dispensed through a licensed pharmacy. It carries the highest confidence on manufacturing quality and usually the highest monthly cost.
The manufacturer is not the only place a branded self-pay figure is published. Direct-to-consumer practices such as Ro, Henry Meds, and HealthRX keep public pages listing what they charge in cash for branded Wegovy, and reading two or three of those against the manufacturer’s own quote is the quickest way to tell whether the direct channel is really the cheapest one at a given dose.
Route two: an agent the plan already covers
Where the sponsor does cover weight management but prefers a different product, the least painful path is often the preferred one. The injectable field in the United States includes semaglutide 2.4 mg, liraglutide 3.0 mg, and tirzepatide, each with its own labeling and its own trial record. Reading those trials against each other is a trap, because STEP-1 and SURMOUNT-1 were separate studies with different populations and cannot be treated as a head-to-head result. A direct comparison of semaglutide and tirzepatide has been published on its own terms, and a prescriber is far better placed than a formulary to judge which agent fits a given person.
Route three: asking for an exception
An exception request asks the plan to pay for a non-preferred or excluded product for one specific member on clinical grounds. It is worth filing when the category is covered and the particular product is not. It is close to futile when the sponsor excluded the entire category, because an exception process cannot manufacture a benefit nobody bought. Establishing which case applies before spending weeks on paperwork saves more time than any other single step.
Route four: cash telehealth and compounded semaglutide
Compounded semaglutide is prepared by a compounding pharmacy rather than made under an approved application. FDA states plainly that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before they reach patients. Pharmacovigilance analysis of compounded GLP-1 products and a published case series on administration errors both point at dosing and device confusion as recurring failure modes, which is an argument for programs that supervise dose changes rather than ship a vial and step back.
Several cash practices post their monthly figures publicly, among them Ro, Hims & Hers, and FormBlends, which pairs its pricing with a written account of how a pharmacy benefit tends to treat this drug class. Once the numbers are on one page the comparison takes minutes.
| Route | What it is | What sets the price | Main limitation |
|---|---|---|---|
| Manufacturer self-pay | Approved product bought direct | Program terms and pack size | Highest monthly outlay |
| Covered alternative | The plan’s preferred agent | Copay tier and deductible status | Only exists if the category is covered |
| Exception request | Clinical case for a non-preferred drug | Nothing further, if granted | Cannot create an excluded benefit |
| Cash telehealth, compounded | Supervised prescription, non-approved product | Flat monthly fee, sometimes dose | No FDA approval of the finished drug |
Compare totals, not headline prices
The monthly drug figure is only part of what a household pays. Visit fees, laboratory work, shipping, and the price change that arrives with a dose increase all belong in the same column. Twelve months is the honest unit, because the evidence on stopping is unambiguous: in the STEP-1 trial extension, participants regained around two-thirds of the weight they had lost within a year of withdrawal. A program affordable for two months and not for twelve is a purchase rather than a plan.
Questions people ask
Does a manufacturer savings card help when the plan excludes the drug?
Usually not in the way people expect. Copay assistance is generally built for members whose commercial plan does cover the product and leaves a residual cost share. Where the category is excluded outright, the relevant offer is the separate self-pay price rather than the copay card, and the two carry different terms.
Is compounded semaglutide simply the same medicine at a lower price?
Not in regulatory terms. The active molecule may be the same, but the finished product has not been through federal review for safety, effectiveness, manufacturing quality, or labeling. That gap is precisely why the supervision attached to the prescription matters more here than it does with an approved product bought at a retail counter.
Can an employer add the benefit part way through the year?
Rarely. Benefit design moves on an annual cycle tied to the plan year, and mid-year additions are unusual outside a change of carrier or administrator. Raising the gap with a benefits committee ahead of the renewal window is the version of this request that occasionally succeeds.
Is moving to a covered alternative a downgrade?
Not necessarily. Approved anti-obesity agents differ in mechanism, dosing schedule, and average results, and the preferred product on one formulary is the non-preferred one on another. Guideline reviews treat several of them as reasonable starting choices, which makes formulary preference a weak signal about clinical quality.
What should be priced before anything is started?
Three numbers, for a full year: the manufacturer self-pay total, the total for whatever the plan does cover including deductible, and the all-in total from any cash program under consideration. Most people discover the ranking is not what they assumed once shipping and visit fees are included.
